- This is part 4 in a continuing series on building a dividend income equity portfolio with lower market risk and boosted yield using covered option writing.
- A preliminary screen identifies 87 candidate tickers for further study. This list was further narrowed to 16 with suitable option yields available.
- This installment evaluates GlaxoSmithKline for quality, value, and covered option writing boosts as part of the Tortoise portfolio.
- Don't be too fast to swallow GSK right now. It may be the wrong medicine for your portfolio.